| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Powder |
| Purity: | >99% |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| Product name: | Afatinib (BIBW 2992);Gilotrif |
| Synonyms: | BIBW 2992;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;Tovok;Tovok, BIBW 2992;BIBW2992 Afatinib;Afatinib (BIBW 2992);ToMtovok;(S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide |
| CAS: | 439081-18-2 |
| MF: | C24H25ClFN5O3 |
| MW: | 485.944 |
| Purity: | 99.5% min |
| Appearance: | White or Nearly White Crystalline Powder |
| MOQ: | 10G |
| Specifications: | Pharmaceutical Grade |
| Deliver time: | About 5 days |
| Deliver methods: | TNT,EMS,HKEMS,DHL,ect.(door to door) |
Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim.
It acts as a angiokinase inhibitor.
Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal
growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only active against
EGFR mutations targeted by first generation TKIs likeerlotinib or gefitinib, but also against those not sensitive to these
standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as
other EGFR and Her2 driven cancers.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}